80 Participants Needed

Metformin + Exercise for Metabolic Syndrome

Recruiting at 2 trial locations
SK
JD
Overseen ByJaclyn Dosik, MEd
Age: 18+
Sex: Any
Trial Phase: Phase 2 & 3
Sponsor: Rutgers, The State University of New Jersey
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

Arterial disease is the leading cause of morbidity/mortality in Metabolic syndrome (MetS). This occurs early as evidenced by arterial dysfunction that, in turn, raises blood pressure and glucose. Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular risk. However, the optimal exercise dose to be combined with metformin for additive effects on vascular function is unknown. Based on the investigator's preliminary work, the overall hypothesis is that metformin blunts adaptation following high intensity exercise training (HiEx) by lowering mitochondrial derived oxidative stress signaling. The investigators further hypothesize that low intensity exercise (LoEx) training combined with metformin will promote additive effects on vascular function compared to LoEx or HiEx+metformin, and maintain/improve non-exercise physical activity patterns. In this double-blind trial, obese 30-60y MetS participants will be randomized to: 1) LoEx+placebo; 2) LoEx+metformin, 3) HiEx+placebo; or 4) HiEx+metformin for 16 weeks.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are taking medications that affect heart rate and rhythm or active weight suppression medications, you may not be eligible to participate.

What evidence supports the effectiveness of the treatment combining metformin and exercise for metabolic syndrome?

Research shows that exercise alone is more effective than metformin in improving insulin resistance and fat oxidation in overweight and obese adults. However, metformin is known to help with glucose tolerance and prevent diabetes progression in insulin-resistant patients.12345

Is the combination of metformin and exercise safe for humans?

Research indicates that metformin and exercise are generally safe when used together in humans. Studies have not shown significant negative effects on muscle function or metabolic responses, suggesting that this combination is well-tolerated.23678

How does the treatment of Metformin combined with exercise differ from other treatments for metabolic syndrome?

The combination of Metformin and exercise for treating metabolic syndrome is unique because it targets insulin resistance, a key factor in the condition, by using both a medication that improves glucose tolerance and physical activity that enhances fitness and body composition. However, there is conflicting evidence on whether Metformin might reduce the benefits of exercise, making this combination a novel area of study compared to using either treatment alone.1291011

Research Team

SK

Steven K Malin, PhD

Principal Investigator

Rutgers, The State University of New Jersey

Eligibility Criteria

Adults aged 40-80 with Metabolic Syndrome, not currently on metformin or engaging in significant exercise, who have a BMI between 25 and 47. Participants should have risk factors like high blood pressure, large waist circumference, or a family history of diabetes but cannot be diabetic themselves. Excludes those with serious health conditions, non-English speakers, recent smokers, pregnant/nursing women, and anyone on certain heart medications.

Inclusion Criteria

I do not have Type 2 diabetes.
I am a man over 45 or a woman over 55.
My parent or sibling has type 2 diabetes.
See 19 more

Exclusion Criteria

I am currently on medication to help with weight loss.
You don't exercise regularly by doing moderate or high intensity activities for at least 30 minutes, at least 2 times a week.
You have a history of serious health issues that could affect the study results or your safety.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo 16 weeks of exercise training combined with either metformin or placebo, with varying exercise intensities

16 weeks
3 supervised training sessions and 2 unsupervised training sessions per week

Follow-up

Participants are monitored for changes in vascular and metabolic insulin sensitivity

4 weeks

Treatment Details

Interventions

  • Exercise
  • Metformin
  • Placebo
Trial OverviewThe trial is testing the combination of low (LoEx) or high intensity (HiEx) exercise with either metformin or placebo to see which improves vascular health in obese adults with Metabolic Syndrome. It's a double-blind study where participants are randomly assigned to one of four groups for 16 weeks.
Participant Groups
4Treatment groups
Active Control
Placebo Group
Group I: LoEx+MetforminActive Control2 Interventions
Subjects randomly assigned to this group will participate in the same 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not find out whether or not they are on Metformin until after the study is complete. If their doctor needs to know, the people doing this study can find out. Drug: Low Intensity Exercise + Metformin Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
Group II: HiEx+MetforminActive Control2 Interventions
Subjects randomly assigned to this group will participate in the same HiEx 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin. Drug: High Intensity Exercise + Metformin High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
Group III: LoEx+PlaceboPlacebo Group2 Interventions
Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo. Drug: Low Intensity Exercise + Placebo Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
Group IV: HiEx+PlaceboPlacebo Group2 Interventions
Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo. Drug: High Intensity Exercise + Placebo High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rutgers, The State University of New Jersey

Lead Sponsor

Trials
471
Recruited
81,700+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

In a study of 75 insulin-resistant patients, exercise training alone or combined with metformin (MET) significantly improved maximal aerobic capacity (peak VO2), while MET alone showed no improvement.
Both exercise training groups (with and without MET) reported significant enhancements in quality of life, indicating that exercise should be prioritized as the primary therapy for insulin resistance, even when MET is included.
Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients.Cadeddu, C., Nocco, S., Cugusi, L., et al.[2021]
In a study involving 251 participants with type 2 diabetes, metformin users showed a significant reduction in HbA1c levels after aerobic training compared to control, while non-users did not show this benefit.
Metformin did not negatively impact changes in fitness, body weight, or waist circumference resulting from exercise, suggesting it does not hinder the positive effects of exercise on glycaemic control.
Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both?Boulé, NG., Kenny, GP., Larose, J., et al.[2022]
In a study involving seven healthy swimmers, metformin intake (500 mg) was found to increase the anticipation of blood lactate peak concentration during high-intensity swimming intervals, suggesting a potential metabolic efficiency benefit.
However, metformin did not significantly affect neuromuscular responses, perceived exertion, or overall swimming performance, indicating that while it may influence certain metabolic parameters, it does not enhance athletic performance in this context.
Metformin anticipates peak of lactate during high-intensity interval training but no changes performance or neuromuscular response in amateur swimmers.Norberto, MS., De Arruda, TB., Cursiol, JA., et al.[2022]

References

Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients. [2021]
Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? [2022]
Metformin anticipates peak of lactate during high-intensity interval training but no changes performance or neuromuscular response in amateur swimmers. [2022]
Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. [2023]
The Effect of Metformin on Self-Selected Exercise Intensity in Healthy, Lean Males: A Randomized, Crossover, Counterbalanced Trial. [2022]
Metformin's effect on exercise and postexercise substrate oxidation. [2019]
Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials. [2022]
Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study. [2023]
[Physical training in the treatment of metabolic syndrome]. [2017]
Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial. [2020]
Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness. [2014]